Cantor Fitzgerald initiated coverage of NeuroPace with an Overweight rating and $11 price target. The firm holds a favorable view of the estimated $2B currently addressable domestic market opportunity with significant room for growth upon indication expansion and believes NeuroPace’s RNS System technology is differentiated from competitors and should serve to drive fast adoption, particularly in expanded indications, the analyst tells investors in a research note. Cantor also views the company’s shares as attractively valued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NPCE:
- NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
- NeuroPace price target raised to $9 from $6 at Wells Fargo